A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1)

This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1296 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Actual Study Start Date: November 16, 2011
Actual Primary Completion Date: June 24, 2014
Actual Study Completion Date: September 20, 2018

Arm:
- Experimental: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)
- Experimental: 80 mg Ixekizumab Dosing Regimen 2 (Q4W)
- Experimental: 80 mg Ixekizumab Dosing Regimen 3 (Q12W)
- Placebo Comparator: Placebo


Related journal:
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.